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PENILAIAN TERAPI ANTIBIOTIK DALAM KALANGAN PESAKIT  
YANG MENGALAMI PNEUMONIA JANGKITAN DARI KOMUNITI 
 DI HOSPITAL PULAU PINANG 
 
ABSTRAK 
Pneumonia jangkitan dari komuniti adalah salah satu penyakit berjangkit 
yang menyebabkan morbiditi dan mortaliti, terutamanya di rantau Asia-Pasifik. Garis 
panduan antibiotik diperlukan untuk mencapai penggunaan antibiotik yang sesuai 
dalam pengurusan pneumonia jangkitan dari komuniti, termasuk Malaysia. Hasil 
terapi masih perlu dipantau untuk menilai penggunaan antibiotik untuk pesakit 
dengan pneumonia jangkitan dari komuniti yang dimasukkan ke hospital. Oleh itu, 
kajian ini bertujuan untuk menilai penggunaan antibiotik untuk pneumonia jangkitan 
dari komuniti di wad perubatan Hospital Pulau Pinang, Malaysia. 
Kajian ini ialah kajian cross-sectional. Data dikumpulkan daripada rekod 
perubatan pesakit yang telah didaftarkan dan disahkan menghidap pneumonia 
jangkitan dari komuniti di Hospital Pulau Pinang, Malaysia dari 1 Januari, 2008 
hingga 31 Disember, 2011. Tiga ratus dua puluh tiga (323) pesakit dipilih 
berdasarkan kriteria penyertaan dan kriteria pengecualian. Antara 323 pesakit, 
terdapat 188 (58.20%) pesakit  yang dirawat dengan antibiotik yang mengikuti garis 
panduan dan 135 (41.80%) pesakit dirawat dengan antibiotik yang tidak mengikuti 
garis panduan. Dalam kumpulan pesakit yang mendapat antibiotik mengikuti garis 
panduan, antibiotik yang paling banyak diberikan adalah amoxicillin/clavulanate + 
azithromycin (77.1%), diikuti oleh ampicillin/sulbactam + azithromycin (16.5%). 
Dalam kumpulan pesakit yang mendapat antibiotik tidak mengikuti garis panduan, 
antibiotik yang diberikan adalah amoxicillin/clavulanate secara monoterapi (37.8%), 
xviii 
 
diikuti oleh ampicillin/sulbactam secara monoterapi (18.5%), macrolide sahaja 
(8.1%), tetracycline + β-lactam/penghalang β-lactamase (9.6%). Hasil kajian 
menunjukkan bahawa terdapat perbezaan yang signifikan dalam pemulihan denyutan 
jantung (p=0.041) dan penurunan sel darah putih (p=0.040) di antara kumpulan 
pesakit yang mendapat antibiotik mengikuti garis panduan dan tidak mengikuti garis 
panduan. Berdasarkan ujian kultur dan pengubahsuaian antibiotik, kajian 
menunjukkan bahawa pemulihan dalam nilai urea (p=0.002) menunjukkan perbezaan 
yang ketara antara enam kumpulan. Tempoh penginapan dalam kumpulan pesakit 
yang mendapat antibiotik mengikuti garis panduan adalah 4.72 ± 2.06 hari, 
sedangkan kumpulan pesakit yang mendapat antibiotik tidak mengikuti garis 
panduan menunjukkan tempoh penginapan 4.90 ± 2.26 hari. Mortaliti hanya didapati 
dalam kumpulan pesakit yang mendapat antibiotik tidak mengikuti garis panduan, 
iaitu sejumlah tiga orang pesakit. 
Penemuan menyimpulkan bahawa antibiotik yang paling banyak diberikan 
kepada pesakit adalah gabungan amoxicillin/clavulanate dan azithromycin. 
Kepatuhan terhadap garis panduan antibiotik menunjukkan keberkesanan dalam 
mengurangkan sel-sel darah putih, memulihkan denyutan jantung pesakit, 
memendekkan tempoh penginapan dan kematian; ujian kultur dan pengubahsuaian 
antibiotik mempengaruhi pemulihan dalam nilai urea. 
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EVALUATION OF ANTIBIOTIC THERAPY 
AMONG PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA  
IN HOSPITAL PULAU PINANG 
 
ABSTRACT 
Community-acquired pneumonia (CAP) is one of infectious diseases that 
cause morbidity and mortality, especially in Asia-Pacific regions. Antibiotics 
guideline is needed in order to achieve appropriate use of antibiotics for CAP 
management, including Malaysia. Outcome of therapy still needed to be monitored to 
evaluate the antibiotics use for hospitalized patients with CAP. Therefore, this study 
was aimed to evaluate antibiotics use for community-acquired pneumonia (CAP) in 
medical ward of Hospital Pulau Pinang, Malaysia. 
This was cross-sectional study. Data were collected from medical record of 
patients that had been registered and diagnosed with CAP in Hospital Pulau Pinang, 
Malaysia from January 1, 2008 until December 31, 2011. Three hundred and twenty 
three (323) patients were selected based on inclusion and exclusion criteria. Among 
323 patients, there were 188 (58.20%) patients treated with antibiotics according to 
the guideline and 135 (41.80%) patients received antibiotics discordant to guideline. 
In guideline-adherent group, the most prescribed antibiotics were 
amoxicillin/clavulanate + azithromycin (77.1%); followed by ampicillin/sulbactam + 
azithromycin (16.5%). While in guideline-discordant group, the most commonly 
prescribed antibiotics were amoxicillin/clavulanate monotherapy (37.8%); followed 
by ampicillin/sulbactam monotherapy (18.5%), macrolide alone (8.1%), tetracycline 
+ β-lactam/β-lactamase inhibitor (9.6%). Study findings also showed that there were 
significant differences in the improvement for heart rate (p=0.041) and white blood 
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cell (WBC) reduction (p=0.040) between guideline-adherent and guideline-
discordant group. Based on culture tests and modification of antibiotics, findings 
suggested; patients’ improvement in urea level (p=0.002) were significantly different 
among six groups. Length of stay (LOS) in guideline-adherent group was 4.72 ± 2.06 
days, while guideline-discordant group showed length of stay (LOS) of 4.90 ± 2.26 
days. Deaths were only found in guideline-discordant group with three patients.  
Study findings concluded that the most common antibiotic that had been 
prescribed was combination of amoxicillin/clavulanate and azithromycin. 
Application of available antibiotic guideline of CAP showed effectiveness in 
reducing white blood cells (WBC) count, improving heart rate of patients, shortening 
length of stay (LOS) and no mortality; culture tests and modification of antibiotics 
affected patients’ improvement in urea level.  
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CHAPTER 1 
INTRODUCTION 
 
1.1. Background 
Community-acquired pneumonia (CAP) is one of infectious diseases that 
cause morbidity and mortality, especially in Asia-Pacific regions (Song et al., 2011). 
It is one of pulmonary infections that ranging from self-limited processes to life-
threatening infections and from acute diseases to chronic inflammatory diseases 
(Simon, 2003). It is inflammation or infection of lungs that causes lungs dysfunction 
(Lutfiyya et al., 2006).   
The choice of antibiotics therapy ensures appropriate coverage of causative 
microorganisms in hospitalized patients with CAP (Ho et al., 2009). Selection of 
antibiotics based on severity of illness, presumptive microorganisms, local resistance 
patterns of the microorganisms and co-morbid conditions (Lutfiyya et al., 2006; 
MOH, 2008; Ho et al., 2009). The physician should decide the need and reason for 
therapy, select the appropriate antibiotics, dose, frequency, route of administration 
and duration of use (Guven and Uzun, 2003). Therefore, a specific antibiotic 
guideline is needed in order to achieve appropriate use of antibiotics for CAP 
management.  
Some guidelines had been made by several organizations such as American 
Thoracic Society (ATS), British Thoracic Society (BTS), Canadian Society of 
Infectious Diseases and others. However, treatment for CAP in Asian countries, 
including Malaysia, should be based on epidemiological data of microorganisms and 
antibiotics resistance (Song et al., 2008). As the most common causative 
microorganism for CAP, Streptococcus pneumoniae resistance to β-lactams is 
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increasing (Song et al., 2004a; Song et al., 2004b; Song et al., 2008). But, 
Streptococcus pneumoniae isolates are still susceptible to β-lactams in some CAP 
studies in Asia, including Malaysia. Therefore, β-lactams still become the choice of 
antibiotic for CAP guideline therapy due to their sensitivity against Streptococcus 
pneumoniae (Rohani et al., 1999; Wattanathum et al., 2003; Song et al., 2008; Ishida 
et al., 2008).  
The occurrence of atypical microorganisms that cause CAP is increasing 
(Shevet et al., 2005). Even though a review defines that antibiotics for atypical 
microorganisms in hospitalized CAP patients do not give benefit for survival or 
clinical efficacy (Shevet et al., 2005), current guidelines recommend the use of 
antibiotics that may cover atypical microorganisms (Mandell et al., 2000; Mandell et 
al., 2007; MOH, 2008; Lim et al., 2009). Those antibiotics are consisted of 
combination of β-lactam and macrolide or fluoroquinolone monotherapy (Mandell et 
al., 2000; Mandell et al., 2007; Calzada et al., 2007; MOH, 2008; Lim et al., 2009; 
Tessmer et al., 2009). Addition of macrolide to a β-lactam regimen or 
fluoroquinolone monotherapy for CAP treatment may improve survival and length of 
stay (LOS) (Martinez, 2004). But, some guidelines restrict the use of fluoroquinolone 
regarding increased number of microorganisms that become resistant to 
fluoroquinolone (Song et al., 2004b; Mandell et al., 2007; MOH, 2008; Lim et al., 
2009).  
In some studies, patients that received antibiotics according to guideline 
showed better outcomes than those who received antibiotics discordant to guideline 
(Arnold et al., 2009; Tessmer et al., 2009). Outcomes included time to reach clinical 
stability, length of stay (LOS) and mortality (Arnold et al., 2009; Tessmer et al., 
2009). Treatment failure was also lower in guideline-adherent group (Arnold et al., 
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2009; Tessmer et al., 2009). Otherwise, some studies showed that length of stay 
(LOS) and mortality in guideline-adherent group were not significantly different 
between guideline-adherent group and guideline-discordant group (Marras et al., 
2004; Calzada et al., 2007). It is important to evaluate the outcome therapy of CAP 
even though some studies do not show better outcomes from the impact of applied 
guideline in treating hospitalized patients with CAP. However, antibiotics guideline 
must be taken into consideration when selecting the appropriate antibiotics for 
therapy of CAP, including Malaysia. Outcome of the therapy still needed to be 
monitored to evaluate the antibiotics use for hospitalized patients with CAP.  
 
1.2. Epidemiology of Community-Acquired Pneumonia (CAP) 
Lower respiratory tract infections (LRTIs), including CAP, was placed third 
among 20 leading causes of death (WHO, 2008). There was a study that included 
4337 patients from four regions. The study showed the incidence of CAP due to 
atypical pathogens for 22% in North America, 28% in Europe, 21% in Latin America 
and 20% in Asia and Africa (Arnold et al., 2007). Community-acquired pneumonia 
(CAP) infections were endemic in the Asia region (Ngeow et al., 2005).  
Community-acquired pneumonia (CAP) showed incidence 3-5 cases per 1000 
persons and mortality rate approximately of 5-15% in hospitalized patients (Kaplan 
et al., 2002). Most patients with CAP were treated in ambulatory care, while 20% of 
CAP patients were hospitalized and 1% of CAP patients required treatment in an 
Intensive Care Unit (Glover and Reed, 2008). Mortality rate for hospitalized patients 
with CAP was estimated for 5.1-13.7% (Marston et al., 1997).  
A prevalence study was conducted at 12 medical centers in Beijing, 
Shanghai, Hong Kong, Seoul, Taipei, Bangkok, Manila, Kuala Lumpur, Petaling 
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Jaya, Singapore, Jakarta, Surabaya. Most patients in this study were admitted to 
hospital for treatment of CAP. Among 1374 patients with CAP diagnosis, 821 
(88.7%) patients were admitted to hospital and 56 (6%) patients required treatment in 
the Intensive Care Unit (ICU). This study stated that CAP infections were endemic in 
the region (Ngeow et al., 2005).  
Epidemiology study of Streptococcus pneumoniae infection was conducted in 
Malaysia. A study conducted by Rohani et al (1999) in the six study centers in 
Malaysia obtained 273 isolates of Streptococcus pneumoniae. Community-acquired 
pneumonia (CAP) was the main clinical manifestation of pneumococcal infections. A 
prospective study was conducted to predict in-patient mortality in 108 hospitalized 
patients with CAP in Malaysia. The study showed that 13 (12%) patients died in 
hospital while 95 (88%) patients survived (Loh et al., 2004). There was a 
retrospective study that included 313 cases of Klebsiella pneumoniae infections. In-
hospital mortality and requirement for ventilation were 14.3% and 10.8% 
respectively (Loh et al., 2007). Hence, CAP still causes morbidity and mortality in 
respiratory tract infections.  
 
1.3. Clinical Manifestation of Community-Acquired Pneumonia (CAP) 
 
Some microorganisms such as Gram-positive and Gram-negative bacteria can 
cause CAP, with similar clinical characteristics. Pneumococcus, Staphylococcus, the 
enteric Gram-negative rods may cause local irritation or destruction of blood vessels 
that can lead to rust-colored sputum or hemoptysis (Glover and Reed, 2008).   
Bacterial pneumonia is caused by Gram-positive such as Streptococci, 
Staphylococci and Gram-negative organisms that inhabit the gastrointestinal tract 
(enterics), soil and water (non-enteric) (Lim et al., 2009). The chest radiograph 
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reveals a dense lobar or segmental infiltrate that indicate Gram-positive and Gram-
negative bacterial infection. Sputum gram stain shows predominant organism, which 
is reflected as growth of a single species on culture (Glover and Reed, 2008). The 
complete blood count test shows leukocytosis with a predominance of 
polymorphonuclear cells. White blood cell (WBC) may increase or remain normal in 
bacterial infection. The patient also may suffer low oxygen saturation on arterial 
blood gas or pulse oximetry (Glover and Reed, 2008). 
 
Table 1.1. Clinical Manifestation of Pneumonia (Simon, 2003; Lutfiyya et al., 
2006; Glover and Reed, 2008)  
Signs and symptoms Physical examination 
1. Fever  
2. Chills  
3. Dyspnea  
4. Productive cough 
5. Rust-colored sputum or 
hemoptysis 
6. Pleuritic chest pain 
1. Tachypnea and tachycardia  
2. Dullness to percussion  
3. Diminished breath sounds 
over affected area 
4. Inspiratory crackles during 
lung expansion 
Chest radiograph Laboratory tests 
1. Dense lobar  
2. Segmental infiltrate 
1. Leukocytosis with 
predominance of 
polymorphonuclear cells  
2. Low oxygen saturation on 
arterial blood gas or pulse 
oximetry 
 
 
1.4. Antibiotics Therapy for Hospitalized Patients with Community-Acquired 
Pneumonia (CAP)  
 
Antibiotics therapy is needed in treating hospitalized patients with CAP. 
Antibiotics choices are classified into preferred and alternative recommendations 
based on clinical evidence of effectiveness and adverse effects (MOH, 2008). 
Antibiotics prescribing should be made based on the presumptive etiologic 
microorganisms, local susceptibility pattern and patients’ co-morbidities. Information 
on pattern of antibiotics use is essential regarding management on antibiotics 
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prescribing (MOH, 2008). The use of guidelines can promote the appropriate 
management of CAP (File and Hadley, 2002).  
In American guideline, antibiotics treatments for hospitalized patients with 
CAP are initially given fluoroquinolone alone or macrolide plus β-lactam (Mandell et 
al., 2007). Patients with recent antibiotics therapy are given an advanced macrolide 
plus a β-lactam or fluoroquinolone alone (Mandell et al., 2007). In Canadian 
guideline, the use of fluoroquinolone alone is recommended (Mandell et al., 2000). 
Development of resistance to these fluoroquinolones has already been reported 
(Liam, 2005). Despite a high level of activity against Streptococcus pneumoniae and 
atypical organisms, fluoroquinolones are not recommended because of their 
overextended spectrum of coverage that include Gram-negative bacteria and the 
emergence of resistant Streptococcus pneumoniae (Liam, 2005). The use of a third-
generation cephalosporin and a macrolide antibiotic provides better coverage for 
CAP without causing Streptococcus pneumoniae resistance but also of the 
emergence of many resistant Gram-negative organisms that are not related with the 
patient's pneumonia (Liam, 2005). Fluoroquinolones are used for certain conditions, 
such as patients who are allergic to first-line agents, failure in first-line therapy, or 
penicillin resistance (Liam, 2005). Community-acquired pneumonia (CAP) that 
caused by penicillin resistant Streptococcus pneumoniae can still adequately treated 
with β-lactams at the right dosage (Liam, 2005). In British guideline, initial 
antibiotics regimens for hospitalized patients with CAP include amoxicillin plus 
clarithromycin or benzylpenicillin plus clarithromycin (Lim et al., 2009). 
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Table 1.2. Antibiotics Therapy for Hospitalized Patients with Community-
Acquired Pneumonia (CAP) That Recommended by American, 
British and Canadian Guideline  
Guideline Preferred therapy Alternative therapy 
American 
Guideline 
(Mandell et al., 
2007) 
Fluoroquinolone alone  or 
macrolide (azithromycin, 
erythromycin or 
clarithromycin) 
 
plus 
 
β-lactam (cefotaxime, 
ceftriaxone, 
ampicillin/sulbactam) 
 
 
British Guideline  
(Lim et al., 2009) 
Amoxicillin 500 mg –1.0 g 
three times in a day given 
orally plus clarithromycin 500 
mg twice a day given orally 
 
(If drugs may not be given orally, use 
IV amoxicillin 500 mg three times in 
a day or IV benzylpenicillin 1.2 g 
four times in a day plus IV 
clarithromycin 500 mg twice in a 
day) 
 
Doxycycline 200 mg loading 
dose then 100 mg given orally 
or levofloxacin 500 mg once in 
a day orally or moxifloxacin 
400 mg once in a day given 
orally 
Canadian 
Guideline  
(Mandell et al., 
2000)  
 
Fluoroquinolone  
 
(Third-generation levofloxacin, 
fourth-generation gatifloxacin and 
moxifloxacin,  are prohibited due to 
severe hepatotoxicity) 
  
Second, third or fourth 
generation of cephalosporin + 
macrolide 
 
 
Based on Ministry of Health, Malaysia, preferred therapy includes IV or oral 
azithromycin or IV/oral erythromycin ethylsuccinate plus third-generation of 
cephalosporins or β-lactams/β-lactamase inhibitors. While CAP which is caused by 
Pseudomonas aeruginosa, preferred treatment includes piperacillin/tazobactam or 
cefepime plus gentamicin plus azithromycin (MOH, 2008).  
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Table 1.3. Guideline of Antibiotics for Hospitalized Patients with Community-
Acquired Pneumonia (CAP) Management in Malaysia (MOH, 2008)  
Infection/Condition and 
Likely Organism 
Recommended Therapy Notes Preferred Alternative 
CAP requiring 
hospitalization 
 (not requiring mechanical 
ventilation) 
Streptococcus pneumoniae 
Mycoplasma pneumoniae 
Haemophilus influenza 
Klebsiella pneumoniae 
Legionella 
Staphylococcus aureus 
Other Gram Negative 
Bacilli (Enterobacter, 
Escherichia coli). 
Azithromycin 500 mg IV/PO 
once in a day 
or 
Erythromycin 500 mg IV 
four times in a day/ 
erythromycin ethylsuccinate 
800 mg PO twice a day 
plus 
Third-generation of 
cephalosporins, such as 
ceftriaxone 1-2g IV once in a 
day 
or 
Lactam/β-lactamase 
inhibitors, such as 
amoxycillin/clavulanate or 
ampicillin/sulbactam 
 
Duration : 1 week 
Levofloxacin 500 mg 
IV/PO once in a day for 1 
week 
1. Empirical therapy for 
melioidosis should be 
considered if patient has 
diabetes mellitus. 
2. Quinolone is used when 
patients failed first line 
regimens or allergic to 
alternative. 
Pseudomonas aeruginosa 
infection 
Piperacillin/tazobactam 4.5 g 
IV three times in a day for 1 
week or  
cefepime 2 g IV twice a day 
for 1 week 
plus 
Gentamicin 5 mg/kg IV once 
in a day  
plus 
Azithromycin 500 mg IV 
once in a day for 1 week 
Piperacillin/tazobactam 4.5 
g IV three times in a day for 
1 week or  
Cefepime 2 g IV twice a 
day for 1 week 
plus 
Ciprofloxacin 500 mg IV 
twice a day for 1 week 
 
The main goals of CAP management include eradicating the causative 
microorganisms, resolving signs and symptoms of CAP, reducing hospitalization and 
preventing relapse (Lutfiyya et al., 2006). Appropriate clinical parameters should be 
evaluated to ensure the efficacy and safety of the therapy (Glover and Reed, 2008). 
Improvement of CAP symptoms such as cough and fever, are important to be 
evaluated. Improvement of symptoms should be observed within the first two days 
(Glover and Reed, 2008). Initial antibiotics therapy should be evaluated if patient’s 
condition is deteriorating within two days (Glover and Reed, 2008). Heart rate, blood 
pressure, respiratory rate, body temperature, oxygen saturation and mental status 
should be measured initially at least twice daily (Lim et al., 2009). The median time 
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for improvement in heart rate and blood pressure is two days and for temperature, 
respiratory rate and oxygen saturation is three days (Lim et al., 2009). Risk factors 
for failure in therapy include multi lobar involvement, occurrence of pleural effusion, 
co-existing liver disease, cancer or neurological disease, Legionella, leucopenia, high 
disease severity on admission and inappropriate antibiotics therapy. Failure may 
increase mortality and length of hospital stay (Lim et al., 2009). 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Introduction 
Community-acquired pneumonia (CAP) still causes morbidity and mortality 
(Loh, 2006). An awareness of the presumptive causative microorganisms of CAP 
treated in certain settings is important to start initial antibiotics therapy (Liam, 2005). 
The choice of antibiotics in treating hospitalized patients with CAP is important as it 
may influence outcomes of therapy (Loh, 2006). 
The use of guidelines may lead to appropriate antibiotics management of 
CAP (File, 2004). Development and application of treatment guidelines should help 
reduce inappropriate prescribed antibiotics (File, 2004). The National Antibiotic 
Guideline 2008, published by Ministry of Health Malaysia, can be important 
guidance for physicians towards making appropriate antibiotics choices for CAP 
(MOH, 2008). Information on pattern of antibiotics use in hospitalized CAP is also 
essential towards control measures on antibiotics that being prescribed (MOH, 2008).  
 
2.2. Etiology of Community-Acquired Pneumonia (CAP) 
Microorganisms that cause CAP could be different in each region. The most 
common causative microorganism worldwide is Streptococcus pneumoniae. Other 
common microorganisms include Mycoplasma pneumoniae, Legionella, 
Chlamydophila pneumoniae, Haemophilus influenzae, and viruses (Glover and Reed, 
2008; Watkins and Lemonovich, 2011). High prevalence of mixed infections by 
bacteria and atypical pathogens also occurred (Almirall et al., 2007; Song et al., 
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2008). Mixed infections occur more in patients with underlying diseases (Gutierrez 
et al., 2005; Almirall et al., 2007).   
Streptococcus pneumoniae was still the most common microorganism that 
caused CAP in some countries in Asia (Ishida et al., 1998; Wattanathum et al., 2003; 
Miyashita et al., 2005; Ngeow et al., 2005; Song et al., 2008). Table 2.1 showed 
common microorganisms etiology for hospitalized patients with CAP in some 
countries in Asia, including Malaysia. Song et al conducted a study in China, South 
Korea, Hong Kong, India, Singapore, Vietnam, Philippines, Taiwan, regarding 
microorganisms that caused hospitalized CAP patients. This study showed 
Streptococcus pneumoniae (29.2%), Klebsiella pneumoniae (15.4%), Haemophilus 
influenza (15.1%), Pseudomonas aeruginosa (6.7%) as the most common causative 
microorganisms of CAP in the region (Song et al., 2008). Studies that conducted by 
Miyashita and Ishida stated that Streptococcus pneumoniae, Haemophilus influenzae 
and Mycoplasma pneumoniae were the etiology of CAP in Japan (Miyashita et al., 
2005; Ishida et al., 1998). In Thailand study, the most common causative 
microorganisms for CAP were Streptococcus pneumoniae (22.4%), Chlamydophila 
pneumoniae (16.3%), Klebsiella pneumoniae (9.5%), Mycoplasma pneumoniae 
(6.8%) (Wattanathum et al., 2003; Ngeow et al., 2005). However, etiology for CAP 
in Malaysia were quite different to those in other countries in Asia; they were 
Klebsiella pneumoniae (17.8%), Mycobacterium tuberculosis (15.1%), Acinetobacter 
(4.1%), Pseudomonas (2.7%) (Loh et al., 2004). 
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Table 2.1. Common Causative Microorganisms for Hospitalized Patients with 
Community-Acquired Pneumonia (CAP) 
Literature No. of patients Etiology of CAP 
 Song et al., 2008 
955 
Streptococcus pneumoniae (29.2%), Klebsiella 
pneumoniae (15.4%), Haemophilus influenzae (15.1%), 
Pseudomonas aeruginosa (6.7%) 
Miyashita et al., 2005 400 Streptococcus pneumoniae (26.3%), mixed infection 
(14.0%), Haemophilus influenzae (13.0%), Mycoplasma 
pneumoniae (9.3%) 
Ishida et al., 1998 318 Streptococcus pneumoniae (23.0%), Haemophilus 
influenzae (7.4%), Mycoplasma pneumoniae (3.4%) 
Wattanathum et al., 2003; 
Ngeow et al., 2005 
 
147 Streptococcus pneumoniae (22.4%), Chlamydophila 
pneumoniae (16.3%), Klebsiella pneumoniae (9.5%), 
Mycoplasma pneumoniae (6.8%) 
Loh et al., 2004 
 
108 Klebsiella pneumoniae (17.8%), Mycobacterium 
tuberculosis (15.1%), Acinetobacter (4.1%), 
Pseudomonas (2.7%) 
 
Klebsiella pneumoniae was the highest number of causative microorganism 
in hospitalized CAP patients in Malaysia (Loh et al., 2004). A study by Kin showed 
that common causative microorganisms in hospitalized patients with CAP (n=352) in 
Kuala Lumpur, were Klebsiella pneumoniae (11.4%), Mycoplasma pneumoniae 
(6.3%), Mycobacterium tuberculosis (4.8%), Staphylococcus aureus (3.7%), 
Streptococcus pneumoniae (3.4%), Haemophilus influenzae (3.1%). While common 
causative microorganisms in hospitalized patients with CAP (n=98) in Penang were 
Mycobacterium tuberculosis (15.3%), Klebsiella pneumoniae (7.2%), Pseudomonas 
aeruginosa (6.1%), Staphylococcus aureus (5.0%), Streptococcus pneumoniae 
(3.0%), Acinetobacter (3.0%) (Liam, 2005). Thus, it is important that the choice of 
antibiotics therapy ensures appropriate coverage of potentially causative 
microorganisms in hospitalized patients with CAP. 
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2.3. Initial Antibiotics Therapy for Hospitalized Patients with Community-
Acquired Pneumonia (CAP) 
 
Antibiotics therapy is needed for CAP patients that require hospital treatment. 
Initial antibiotics therapy should be given to these patients. Initial antibiotics may be 
administered through intravenous or oral administration (Loh et al., 2004). Earlier 
administration of initial antibiotics was required in order to get better clinical 
outcome and improve survival rate (Restrepo and Anzueto, 2005). 
Antibiotics therapy must cover Streptococcus pneumoniae and atypical 
microorganisms (Restrepo and Anzueto, 2005). A study showed that length of stay 
(LOS) was 8.8 ± 7.2 days for patients who received atypical coverage (n=2.220) and 
9.6 ± 7.0 days for patients who did not receive atypical coverage (n=658). The mean 
difference was statistically significant. This study also showed decreased patient 
mortality in patients who received atypical coverage (Arnold et al., 2007).  
Antibiotics that had atypical coverage for hospitalized patients with CAP 
were also advantageous for patients with Legionella infection (Shevet, et al., 2005). 
A meta-analysis showed that in moderate CAP the relative risk for treatment failure 
was significantly lower in patients with Legionella infection that received antibiotics 
against atypical microorganisms (Loh, 2006).  
Combination of β-lactams and macrolides showed better outcomes than β-
lactams monotherapy. A prospective study was conducted between 2002 and 2004 of 
141 adult patients with CAP hospitalized in Seremban Hospital, Malaysia. Sixty-
three (44.7%) patients received a macrolide-containing antibiotic regimen while 78 
(55.3%) patients received single non-macrolide broad spectrum antibiotics. However, 
there were no significant differences in mortality, need of ventilation and median 
length of hospital stay between the two treatment groups (Loh, 2006). Otherwise, 
there were studies that gave different outcome. A review that conducted by Caballero 
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and Rello stated that combination therapy of cephalosporin (β-lactam) and macrolide 
for hospitalized patients with CAP was related to decreased mortality and shorter 
length of stay (LOS) than treatment with cephalosporin (β-lactam) monotherapy 
(Caballero and Rello, 2011). The other study that showed the superiority of β-lactam 
plus macrolide was conducted by Martinez et al (2003). The study included 409 
hospitalized patients with CAP diagnosis. Two hundred and thirty eight (58%) 
patients received β-lactam plus macrolide and 171 (42%) patients received β-lactam 
without macrolide. Multivariate analysis revealed that one of the variables, no 
inclusion of macrolide in the initial antibiotics regimens, was associated with death. 
Patients with bacteremic pneumococcal pneumonia, not adding macrolide to β-
lactam-based initial antibiotics regimens may cause in-hospital mortality (Martinez et 
al., 2003). 
Antibiotics therapy that used β-lactam monotherapy did not give better 
outcomes than β-lactam plus macrolide or fluoroquinolone monotherapy. A 
systematic review was conducted to evaluate whether β-lactam plus macrolide or 
fluoroquinolone monotherapy excel β-lactam monotherapy. Eight relevant studies 
were included in this review. The review showed that β-lactam plus macrolide or 
fluoroquinolone monotherapy reduced mortality, reduced length of stay (LOS) in one 
study and showed no beneficial effects in one study.  This was caused by 
unrecognized role of atypical pathogens, anti-inflammatory effects of macrolide or 
resistance to β-lactam (Oosterheert et al., 2003).  
The use of fluoroquinolones in CAP management is also getting increase, due 
to its effectiveness. A meta-analysis of randomized controlled trials that conducted 
by Vardakas et al showed fluoroquinolones were more effective than a combination 
of β-lactams and macrolides. It was stated that fluoroquinolones showed higher 
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success in treating CAP. But, mortality rates between fluoroquinolones and other 
comparator antibiotics were not different (Vardakas et al., 2008). Higher success in 
treating CAP with fluoroquinolones was caused by zero baseline resistance to these 
antibiotics compared to higher resistance for β-lactams and macrolides. 
Unfortunately, resistance to fluoroquinolones might increase in the future (Vardakas 
et al., 2008).  
There were studies that supported the equal effectiveness of combination of 
β-lactams and macrolides, compared to fluoroquinolones. A study conducted at 
Veterans Affairs Hospital revealed that mortality rates were lower among PSI Class 
V patients in combination of β-lactams and azithromycin than in levofloxacin 
monotherapy group. But, the mortality rates among PSI Class I-IV patients were not 
different between two groups (Lodise et al., 2007). The other retrospective study of 
12945 inpatients showed that initial treatment of CAP with second-generation 
cephalosporin plus macrolide, third-generation cephalosporin plus macrolide or 
fluoroquinolone monotherapy was associated with reduction of 30-day mortality in 
patients with PSI classes IV and V (Gleason et al., 1999). 
The other study also pointed the use of cephalosporin group and doxycycline 
as initial antibiotics for CAP requiring hospitalization. A total of 216 patients of 
hospitalized CAP were treated with ceftriaxone plus doxycycline and 125 received 
other appropriate initial antibiotics. The result showed that ceftriaxone plus 
doxycycline could reduce inpatient mortality and 30-day mortality. However, 
ceftriaxone and doxycycline therapy did not reduce length of stay (LOS) and 
readmission rates (Flanders et al., 2006).  
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2.4. Antibiotics Modification in Community-Acquired Pneumonia (CAP) 
Management 
 
Positive blood culture results could be useful in CAP management. 
Antibiotics modification may occur due to positive blood culture results. But, cost-
effectiveness needs to be assessed in prospective clinical trials (Waterer et al., 1999). 
Initial broad-spectrum antibiotics are given to hospitalized patients with CAP. 
Therefore, the possible influence to antibiotics modification for CAP is either 
reduction or narrowing antibiotics therapy. Antibiotics modification was consisted of 
any change in the dose of antibiotic, addition or discontinuation of one or more 
antibiotics (Waterer et al., 1999). Seventy-four patients with pneumococcemia 
admitted into a study. Blood culture results altered management in 31 (41.9%) 
patients; two of patients had antibiotics modification due to antibiotics resistance. 
Antibiotics modification was consisted of macrolide stopped, change to penicillin, 
other antibiotics stopped, add vancomycin or change dose of cephalosporin (Waterer 
et al., 1999).  
Patients (N= 2039) were recruited from 128 centers in ten countries 
(Belgium, France, Germany, Greece, Italy, the Netherlands, Portugal, Spain, Turkey, 
UK). Initial antibiotic treatment modification occurred in 28.9% of patients and was 
more likely in patients with co-morbidities; severely ill patients; patients with 
immune disorders or patients with recurrent episodes of CAP. The most common 
reasons for initial antibiotic treatment modification were insufficient response to 
treatment (12.0%) and adverse events (2.0%) (Blasi et al., 2013).  
Antibiotics therapy for hospitalized patients with CAP must be switched from 
intravenous to oral administration. An evaluation study stated that this modification 
is associated with significant reduction in the mean of length of hospital stay 
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(Restrepo and Anzueto, 2005). Patients could be discharged directly after changing 
from intravenous to oral administration (van der Eerden et al., 2005). 
 
 
2.5. Antibiotics Therapy for Identified Microorganisms 
 
As stated before, either typical microorganisms (Gram-positive and Gram-
negative bacteria) or atypical microorganisms could cause CAP. As β-lactamase 
production by both Gram-positive and Gram-negative bacteria became major 
concern in CAP management, β-lactamase inhibitors such as clavulanate, sulbactam 
and tazobactam were developed (White et al., 2004). Besides that, newer generation 
of cephalosporins that could endure β-lactamase production was also developed, such 
as third-generation and fourth generation of cephalosporins (Garau, 2005). 
Macrolides were used as alternative therapy for those who had allergy to penicillin 
(Garau, 2001). In CAP management, macrolides were used in combination with β-
lactams/β-lactam inhibitors, due to its activity against atypical microorganisms 
(Flanders et al., 2006). 
A prospective randomized open study performed between 1998 and 2000 
which included 262 hospitalized patients with CAP diagnosis. The two groups 
consisted of empirical broad spectrum antibiotics treatment and pathogen directed 
treatment approach. The study showed that there were no significant differences 
between two groups in LOS, 30-day mortality, clinical failure or resolution of fever. 
This study stated that empirical antibiotics therapy for hospitalized patients with 
CAP has equal clinical efficacy to pathogen directed treatment approach (van der 
Eerden et al., 2005). However, once the pathogen could be identified, adjusted 
antibiotics must be administered (Restrepo and Anzueto, 2005).  
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Identification of specific causative microorganisms within 24–72 hours could 
still be useful for guiding continued treatment. Therapy could be conducted by 
selecting narrow spectrum antibiotics, so that it could reduce the risk of higher 
resistance (File, 2003; Charles, et al., 2008). There are no clear advantages of 
intravenous therapy over oral therapy for antibiotics therapy based on identified 
microorganisms. However, CAP patients who require hospitalization, receive 
intravenous administration (File, 2003).  
 
 
2.6. Outcome of Community-Acquired Pneumonia (CAP) Management 
 
Application of available antibiotic guideline of CAP shows better outcome of 
therapy. These were supported by some CAP studies. One of these studies was a 
study conducted by Tessmer et al (2009) in German that included 1854 hospitalized 
patients with CAP. These patients were treated with antibiotics accordant to 
guideline, either combination of β-lactam and macrolide (51.0%) or β-lactam 
monotherapy (49.0%) Combination of β-lactam and macrolide was associated with 
decreased 14 day mortality and treatment failure at 14 days therapy (Tessmer, et al., 
2009). The other study was conducted by Arnold et al (2009) in order to define the 
outcome therapy of geriatric patients hospitalized with CAP who were treated with 
antibiotics according to 2007 Infectious Diseases Society of America 
(IDSA)/American Thoracic Society (ATS) guideline. This study included 1725 
hospitalized patients. Guideline-adherent group showed decreased time to achieve 
clinical stability, shorter length of stay (LOS), and decreased in-hospital mortality 
than guideline-discordant group. In guideline-adherent group, the most common 
antibiotics were combination of β-lactam and macrolide (58.6%) and quinolone 
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monotherapy (39.7%). In guideline-discordant group, the most common antibiotics 
were β-lactam monotherapy (52.0%) (Arnold et al., 2009).  
Otherwise, application of available antibiotic guideline of CAP did not show 
better outcome of therapy in some CAP studies. Marras et al (2004) reviewed 698 
cases of CAP in Canada, 91.0% (636 cases) were accordant to Canadian Guideline. 
The study stated that there was no significant difference in mortality and length of 
stay (LOS) between guideline-adherent and guideline-discordant group. The most 
common antibiotics were quinolone monotherapy and cephalosporin monotherapy 
(Marras et al., 2004). There was also one study in Spain that pointed the outcome of 
guideline-adherent for antibiotics therapy of CAP. Mortality was analyzed as the 
outcome. But, the mortality rate was higher in non-adherent group than adherent 
group.  It was a prospective study with 425 hospitalized patients with CAP. The 
overall mortality was 8.2%. Mortality in adherent group was 26 (8.2%) while in non-
adherent group was 9 (8.5%). Adherent level to guideline was 76.5% with the 
predominance of combination of β-lactam and macrolide (57.4%). The median 
length of stay was 8 ± 5 days and the re-admission rate was 7.6% (Calzada et al., 
2007). 
Mortality, length of stay (LOS), admission rate to intensive care unit (ICU) 
was higher in patients with Gram-negative infections than those with Gram-positive 
infections (Wattanathum et al., 2003; Loh et al., 2007; Falguera et al., 2009). A 
study enrolled 313 hospitalized patients with CAP and Klebsiella pneumoniae 
isolates. Death was found most common in patients with antibiotic-resistant, 
compared to antibiotic-susceptible patients (10.8% vs 23.3%). But, there were no 
significant differences in length of stay (LOS) between antibiotic-resistant patients 
and antibiotic-sensitive patients (Loh et al., 2007). The other study conducted in 
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Thailand with 147 adult hospitalized patients with CAP. The mortality rate was 
16.3% in the non-ICU hospitalized patients. Mortality rate of Gram-negative 
infections was significantly higher than those Gram-positive infections or atypical 
pathogen infections (53.8% vs 24.4% vs 12.1%) (Wattanathum et al., 2003).  A study 
with 3272 episodes of CAP showed that sixty-one patients (2%) were infected by 
Gram-negative bacilli. Among 61 patients that infected by Gram-negative bacilli, 12 
patients (20%) required intensive care unit (ICU) admission, and the rest of  287 
patients (9%) that not infected with Gram-negative bacilli also required ICU 
admission. Gram-negative bacilli pneumonia patients were also related to increased 
mortality (22 of 61 patients, 36%) compared to patients that not infected with Gram-
negative bacilli (236 of 3211 patients, 7%). Gram-negative bacilli pneumonia 
patients were also related to increased length of stay (LOS), compared to patients 
that not infected with Gram-negative bacilli (16 days vs 9 days) (Falguera et al., 
2009). 
There are some risk factors that can lead to death due to CAP. A study with 
955 hospitalized patients with CAP showed that malignancy, cardiovascular diseases, 
respiratory rate > 30/min and hyponatremia were risk factors that led to death of 
patients (Song et al., 2008). Sepsis had become one of causative conditions that 
could lead death to hospitalized CAP patients (Dionaldo et al., 2007). An 
observational study with 52 hospitalized patients with CAP. Among 52 patients, 
three (6%) died due to sepsis and others were discharged with improved condition. 
Mean of length of stay (LOS) was 9.0 ± 5.0 days (Dionaldo et al., 2007). Other study 
with 3523 patients with CAP; 514 (15%) outpatients, 2521 (72%) patients in ward 
and 488 (14%) patients in intensive care unit (ICU), showed that Streptococcus 
pneumoniae has the highest number for mortality. Besides that, mixed etiologies also 
21 
 
caused high mortality with 32.2% of mixed bacteria with bacteria and 29.3% of 
bacteria and viruses (Cilloniz et al., 2011). Among 318 hospitalized patients with 
CAP that enrolled in a Japan study, 20 (6.1%) patients died during hospitalization. 
Results of culture test of these patients were Streptococcus pneumoniae in three 
patients, Klebsiella pneumoniae in three patients, Streptococcus milleri in two 
patients, Mycobacterium tuberculosis in two patients, Staphylococcus aureus in one 
patient, Staphylococcus aureus + Streptococcus pneumoniae in one patient, 
Klebsiella pneumoniae + Pseudomonas aeruginosa in one patient (Ishida et al., 
1998).  
Death was found most common in patients with antibiotic-resistant, 
compared to antibiotic-susceptible patients (Loh et al., 2007). In one study, antibiotic 
resistance did not influence clinical outcomes and death (Song et al., 2004a). A study 
with 233 adults with pneumococcal pneumonia showed that among 233 patients, 202 
(86.7%) patients showed clinical improvement, 31 (13.3%) patients died within 30 
days after diagnosis. Mortality rates among patients with penicillin resistance, 
cephalosporin resistance or macrolide resistance were not higher than patients with 
antibiotic-susceptibility (Song et al., 2004a). A review of CAP amongst adults in the 
Asia-Pacific region stated that antibiotics resistance did not affect mortality rates 
significantly (Song et al., 2011).  
 
2.7. Problem Statements  
Antibiotics selection for community-acquired pneumonia (CAP) needs 
thorough consideration, due to various microorganisms that may cause CAP. 
Guideline may help antibiotics prescribing for CAP. However, antibiotics prescribing 
that accordant to available guideline need to be evaluated. Antibiotics modification 
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may also occur during CAP management, due to inappropriate initial antibiotics 
therapy, patients’ health status or identified microorganisms. Therefore, antibiotics 
modification also needed to be evaluated. Antibiotics therapy for CAP according to 
guideline should represent better outcome than guideline-discordant therapy. 
Outcome of the therapy should be evaluated, between guideline-adherent therapy and 
guideline-discordant therapy.  
 
2.8.  Rational of Study 
Community-acquired pneumonia (CAP) is an infectious disease that can 
cause increasing morbidity and mortality. Antibiotics therapy is needed in 
hospitalized patients with CAP. Antibiotics selection for CAP management may 
experience some constraints due to various causative pathogens and patients’ health 
status. Choice of antibiotics is important as it can influence its outcome of CAP 
management.  
Many countries have developed guideline for antibiotics therapy in CAP 
treatment, including Malaysia. The National Antibiotic Guideline, published by 
Ministry of Health, Malaysia, can be important guideline for prescribers to make 
appropriate antibiotics choices for CAP. Guideline-adherence in giving antibiotics 
prescription may increase outcome of CAP management.  
Information on pattern of antibiotics prescriptions is also essential to arrange 
control measurement on antibiotics prescribing and its effectiveness. Effectiveness of 
antibiotics therapy that made based on National Antibiotic Guideline, published by 
Ministry of Health, Malaysia need to be evaluated. As comparison, effectiveness of 
antibiotics therapy that made discordant to this guideline also needed to be evaluated. 
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Hopefully, this comparison may help in representing some output to achieve better 
outcome for CAP management.  
 
2.9. Objectives 
2.9.1. General Objective  
This study is aimed to evaluate antibiotics use for community-acquired 
pneumonia (CAP) patients in medical ward of Hospital Pulau Pinang, Malaysia. 
 
2.9.2. Specific Objectives  
1. To identify causative microorganisms of community-acquired pneumonia (CAP) 
in medical ward of Hospital Pulau Pinang, Malaysia. 
2. To evaluate initial antibiotics that being prescribed for community-acquired 
pneumonia (CAP) in medical ward of Hospital Pulau Pinang, Malaysia. 
3. To evaluate antibiotics modification for community-acquired pneumonia (CAP) 
management in medical ward of Hospital Pulau Pinang, Malaysia.  
4. To evaluate antibiotics that being prescribed based on identified microorganisms 
in community-acquired pneumonia (CAP) patients in medical ward of Hospital 
Pulau Pinang, Malaysia.  
5. To evaluate outcome related to community-acquired pneumonia (CAP) 
management in medical ward of Hospital Pulau Pinang, Malaysia. 
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CHAPTER 3 
METHODOLOGY 
 
3.1. Study Design 
This was cross-sectional study. Data were collected from medical record of 
patients that had been registered and diagnosed with CAP. Patients’ list was obtained 
from Chest Ward and Medical Record Office. 
 
3.2. Study Period and Location 
This study was conducted from May -November 2012. It was conducted at 
Hospital Pulau Pinang, Malaysia.  
 
3.3. Population and Sampling Procedure 
3.3.1. Sample Size Calculation 
Sample size calculation was calculated with the pattern below: 
X = Z(c/100)2r(100-r) 
n = N x/((N-1)E2 + x) 
E = Sqrt[(N - n)x/n(N-1)] 
 
 n was the sample size, N was the population size, r was the fraction of 
response and Z(c/100) was the critical value for the confidence level c (Raosoft, 
2004). 
Sample size was calculated with population of patients treated with CAP 
management that counted approximately 1000 patients in medical ward of Hospital 
Pulau Pinang, Malaysia and with confidence level of 95%. Hence, the recommended 
sample size was 278 patients.   
